Correlation Between Inozyme Pharma and BioNTech

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and BioNTech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and BioNTech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and BioNTech SE, you can compare the effects of market volatilities on Inozyme Pharma and BioNTech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of BioNTech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and BioNTech.

Diversification Opportunities for Inozyme Pharma and BioNTech

0.19
  Correlation Coefficient

Average diversification

The 3 months correlation between Inozyme and BioNTech is 0.19. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and BioNTech SE in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioNTech SE and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with BioNTech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioNTech SE has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and BioNTech go up and down completely randomly.

Pair Corralation between Inozyme Pharma and BioNTech

Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the BioNTech. In addition to that, Inozyme Pharma is 1.57 times more volatile than BioNTech SE. It trades about -0.1 of its total potential returns per unit of risk. BioNTech SE is currently generating about 0.25 per unit of volatility. If you would invest  10,356  in BioNTech SE on September 15, 2024 and sell it today you would earn a total of  1,682  from holding BioNTech SE or generate 16.24% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Inozyme Pharma  vs.  BioNTech SE

 Performance 
       Timeline  
Inozyme Pharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
BioNTech SE 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days BioNTech SE has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, BioNTech is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Inozyme Pharma and BioNTech Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Inozyme Pharma and BioNTech

The main advantage of trading using opposite Inozyme Pharma and BioNTech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, BioNTech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will offset losses from the drop in BioNTech's long position.
The idea behind Inozyme Pharma and BioNTech SE pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Complementary Tools

Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine